search

Eledon Pharmaceuticals Inc (ELDN)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
Eledon Gains 13% on Updated Phase 2 Trial Data
Sep 22, 2026

Eledon Gains 13% on Updated Phase 2 Trial Data

Eledon Pharmaceuticals Inc. saw its shares rise 13% after presenting updated long-term data from its Phase 2 trial of tegoprubart, a drug for preventing organ transplant rejection. The data showed improved kidney function and fewer rejections among treated patients compared to standard care. The company plans to initiate a Phase 3 trial in Q4 of this year, following the FDA's fast track designation for tegoprubart.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish